Armistice Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Armistice Capital’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,364,000	Closed	-$5.89M	–	258
2024 Q3	$5.89M	Buy	2,364,000 +28,000	+1%	+$75K	0.09%	113
2024 Q2	$6.17M	Buy	2,336,000 +39,000	+2%	+$93.1K	0.08%	106
2024 Q1	$4.73M	Buy	2,297,000 +108,000	+5%	+$193K	0.06%	125
2023 Q4	$3.94M	Buy	2,189,000 +365,000	+20%	+$507K	0.05%	131
2023 Q3	$2.5M	Sell	1,824,000 -18,803	-1%	-$25.1K	0.04%	131
2023 Q2	$2.52M	Buy	+1,842,803	New	+$3.84M	0.04%	137

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Armistice Capital's ELDN Position: Q4 2024 in Review

Armistice Capital sold out of Eledon Pharmaceuticals (ELDN) in Q4 2024, closing a stake of 2,364,000 shares — an estimated $5.89M sold.

Armistice Capital first reported a position in ELDN in Q2 2023 and held it in 6 quarters. The position peaked at $6.17M in Q2 2024. 75 funds tracked by Wall St. Rank hold ELDN as of Q4 2024.

Armistice Capital reported no remaining Eledon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Armistice Capital sold 2,364,000 Eledon Pharmaceuticals shares in Q4 2024, an estimated $5.89M.
Armistice Capital first reported a position in Eledon Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Armistice Capital's Eledon Pharmaceuticals position peaked at $6.17M in Q2 2024.
75 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.